NCT04636138

Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of Kansas Medical Center · Academic / Other
• Sex: All
• Age: 35 Years – 65 Years
• Healthy volunteers: Accepted

Summary

3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have beneficial effects (prevent stroke, heart attack) but also some bad ones (block some good effects of exercise). Individuals have genetic variations in proteins that metabolize/transport statins. The investigators hypothesize that these variations modulate the relationship between statin use and lack of benefit from exercise. The investigators will test this by having statin-users do supervised exercise for 6 weeks, measuring the cardiorespiratory fitness before/after and correlating this to genetic variations present in the participant.

Conditions

• HMG-CoA Reductase Inhibitor Toxicity

Interventions

Type	Name	Description
OTHER	Exercise	Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.

Timeline

• Start date: 2021-06-03
• Primary completion: 2023-07-30
• Completion: 2026-07-30
• First posted: 2020-11-19
• Last updated: 2025-12-26

Locations

1 site across 1 country: United States